Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer

Tamoxifen is an estrogen receptor (ER) antagonist that is most commonly used for the treatment of ER-positive breast cancer. However, tamoxifen resistance remains a major cause of cancer recurrence and progression. Here, we aimed to identify hub genes implicated in the progression and prognosis of E...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yanyan, Gong, Xiaonan, Zhang, Yujie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2021
Materias:
Bioinformatics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485391/
https://www.ncbi.nlm.nih.gov/pubmed/34406386
http://dx.doi.org/10.1042/BSR20203020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485391/
https://www.ncbi.nlm.nih.gov/pubmed/34406386
http://dx.doi.org/10.1042/BSR20203020

Ejemplares similares